||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


Addex Extends Parkinson's Disease Collaboration with Merck & Co., Inc.

Geneva, Switzerland, 2 December 2009 - Allosteric modulation company
Addex Pharmaceuticals (SIX:ADXN) announced today the extension of its
research collaboration with Merck & Co., Inc., through an affiliate,
for an additional year. The collaboration is focused on developing
positive allosteric modulators (PAM) of the metabotropic glutamate
receptor 4 (mGluR4) for the treatment of Parkinson's disease and
other undisclosed indications.

Addex will receive research funding from Merck in addition to the
original financial terms, which include milestones and royalties.

Earlier this year Addex disclosed that a preclinical study had shown
that the collaboration had yielded orally available mGluR4 PAM with
efficacy in an animal model of Parkinson's disease.

"We are delighted that Merck values the contribution of our
allosteric modulator discovery platform and wishes to include us in
building further upon the excellent progress this program has made to
date," said Emmanuel Le Poul, head of the CNS Business Unit at Addex.

"Developing innovative non-dopaminergic drugs for Parkinson's disease
is an increasingly important part of our work at Addex," said Vincent
Mutel, CEO of Addex. "We are proud to be advancing mGluR4 PAMs with
our collaborators at Merck."

Under the terms of the exclusive collaboration and license agreement,
first announced in December 2007, Addex received $3 million upfront
and has received two preclinical milestones of $250,000 and $500,000,
to date. Addex is eligible to receive up to $106.5 million in
research, development and regulatory milestones for the first product
developed for multiple indications. Additional milestones of up to
$61 million would be payable if a second and third product is
developed. Addex is eligible to receive undisclosed royalties on
sales of any products resulting from this collaboration. Merck is
responsible for clinical development. Extension of the research
collaboration allows Addex to recognize $1.8 million in research
funding over 12 months beginning on December 1, 2009.

Glutamate, like dopamine and serotonin, is a key neurotransmitter in
the human brain, an important signaling molecule involved in control
of multiple brain functions ranging from motor control to mood. In
Parkinson's disease, the death of dopamine producing neurons leads to
excess glutamate signaling.

Parkinson's disease is a degenerative disease of the brain that often
impairs motor skills, speech, and other functions. It is estimated
that 60,000 new cases are diagnosed each year in the U.S., where more
than 1.5 million people currently have PD. While the condition
usually develops after the age of 65, 15% of those diagnosed are
under 50. PD affects both men and women in almost equal numbers.

mGluR4 may play an important role in Parkinson's disease. Current
treatments focus on dopamine-replacement strategies, however most
patients reach a stage where dopaminergic treatments are no longer
effective. There can also be debilitating side effects with
dopaminergic treatments, especially levodopa induced dyskinesia, and
many patients are encouraged to limit doses so their side effects
will appear later and be less cumbersome. The recent success of
surgical approaches suggests that bypassing the dopamine system may
provide a more effective treatment strategy. It is believed that
selective activation of mGluR4 is one way to do this and could
correct the circuitry that modulates motor excitability via a
non-dopaminergic mechanism.

Published research* shows that mGluR4 activators, like those in
development by Addex and Merck, could work via two distinct
mechanisms to alleviate symptoms of Parkinson's disease and,
potentially, even slow the progression of the disease: 1) mGluR4
activation triggers a compensatory mechanism that may spare or
potentiate the use of dopamine receptor activators; 2) mGluR4
activation may have a neuroprotective effect that helps to preserve
the brain's dopaminergic neurons. Thus, this approach has the
potential to provide significant benefit in Parkinson's disease.

*Nature Reviews Neuroscience, Vol 6, Oct. 2005, pp 787-798

Addex Pharmaceuticals (www.addexpharma.com) discovers and develops
allosteric modulators for human health. Allosteric modulators are a
different kind of orally available small molecule therapeutic agent,
which we believe will offer a competitive advantage over classical
drugs. Our lead allosteric modulator product, ADX10059, an mGluR5
NAM, has achieved clinical proof of concept and is in Phase IIb
testing for the treatment of GERD and, separately, migraine
prevention. ADX48621, an mGluR5 NAM, has completed Phase I testing
and will enter Phase II for PD-LID in 2010. Addex partner
Ortho-McNeil-Janssen Pharmaceuticals, a Johnson & Johnson company, is
performing Phase I testing of ADX71149, an mGluR2 PAM, which has
potential for anxiety and schizophrenia.


Chris Maggos
Head of IR & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos@addexpharma.com


Disclaimer: The foregoing release contains forward-looking statements
that can be identified by terminology such as "not approvable",
"continue", "believes", "believe", "will", "remained open to
exploring", "would", "could", or similar expressions, or by express
or implied discussions regarding Addex Pharmaceuticals Ltd, its
business, the potential approval of its products by regulatory
authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views
of Addex Pharmaceuticals Ltd regarding future events, and involve
known and unknown risks, uncertainties and other factors that may
cause actual results with allosteric modulators of mGluR4, mGluR2 or
mGluR5 to be materially different from any future results,
performance or achievements expressed or implied by such statements.
There can be no guarantee that allosteric modulators of mGluR4,
mGluR2 or mGluR5 will be approved for sale in any market or by any
regulatory authority. Nor can there be any guarantee that allosteric
modulators of mGluR4, mGluR2 or mGluR5 will achieve any particular
levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR4, mGluR2 or
mGluR5 could be affected by, among other things, unexpected actions
by our partners, unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional
analysis of existing clinical data; competition in general;
government, industry and general public pricing pressures; the
company's ability to obtain or maintain patent or other proprietary
intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated,
believed, estimated or expected. Addex Pharmaceuticals is providing
the information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.


This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.



 
 ||| Themen-Infos 
· Mehr zu dem Thema Contracts & Corporate events & IPOs &

Der meistgelesene Artikel zu dem Thema Contracts & Corporate events & IPOs &:
Change on the Board of Directors of Feintool Holding AG

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.075 Sekunden